CD70

Product List

Creative Biolabs offers a wide range of products and services related to CD70 CAR-T cells, catering to various needs and requirements. We also provide comprehensive customization services. Our team of experts works closely with clients to develop personalized CD70 CAR-T cell products tailored to their specific research or treatment goals. Contact us and let us help you in your journey towards groundbreaking discoveries in the research of CD70 CAR-T cells.

Background

CD70, also known as cluster of differentiation 70, serves as a ligand for CD27, a TNFR (tumor necrosis factor receptor) superfamily type I transmembrane glycoprotein. CD70 specifically binds to CD27, which is expressed by activated T and B lymphocytes as well as mature dendritic cells. CD70 is a promising target for antibody-based therapies.

Associated Diseases

• Non-Hodgkin lymphoma
• Melanoma
• Acute myeloid leukemia (AML)

Fig.1 Expression of CD70 on human tumor tissues.¹

Anti-CD70 CAR-T Services

Anti-CD70 CAR-T In Vitro Assay Services

CD70 CAR-T Expression Test

Our CD70 CAR-T cell expression test services include a comprehensive analysis of CD70 expression levels on T cells using cutting-edge technology and state-of-the-art equipment. In addition to our CD70 CAR-T cell expression test services, we offer comprehensive reporting and interpretation of the test results. Based on the findings, our team will offer an in-depth analysis service.

Fig.2 CTX130 potency initially correlates with CD70 expression.²

CD70 CAR-T Cytokine Release Test

Fig.3 ELISA results showed the IFN-γ and IL-2 secretion levels by CD70 CAR.¹

CD70 CAR-T In Vitro Cytotoxicity Assay

Cytokine release assays are rapid and straightforward techniques for assessing the activation of T-cells when stimulated by target cells presenting the candidate peptide. We have accumulated significant expertise in cytokine release assays, and we believe it will accelerate our clients' research progress.

Fig.4 The enhanced tumor-killing ability of CD70 CAR-T cells against target cells.¹

CD70 CAR-T Cell Proliferation Test

Creative Biolabs provides proliferation tests to accurately evaluate the proliferation capacity of CAR-T cells in response to tumor challenges.

Fig.5 The proliferation of CD70-CAR-T cells measured using CFSE assay.³

Anti-CD70 CAR-T In Vivo Assay Services

CD70 CAR-T Cell Therapy Animal Models

Our team has dedicated significant efforts to enhance the CD70 CAR-T Cell Therapy animal models. Firstly, we have developed more sophisticated and accurate models that better mimic human physiological and immune responses. These models incorporate humanized components, such as human immune cells or tissues, enabling us to better study the interactions between CAR-T cells and the human immune system.

Fig.6 The treatment scheme of CAR-T cells T cells and in vivo optical imaging.¹

Efficacy Test of CD70 CAR-T

We have implemented cutting-edge techniques and rigorous protocols to evaluate the efficacy of CAR-T in vivo.

Fig.7 Antitumor response of TanCAR-T cells in human subcutaneous xenograft models.¹

Toxicity Evaluation of CD70 CAR-T

Creative Biolabs has been dedicated to enhancing the evaluation methods for CAR-T cell toxicity, focusing on various aspects. Firstly, we have developed sophisticated in vitro models that mimic the tumor microenvironment to better predict the potential toxic effects of CAR-T cells. These models incorporate factors such as immune cells, tumor cells, and cytokines, creating a complex and realistic environment for toxicity assessment.

Fig.8 Evaluation of hematologic toxicity of CD70-CAR-T cells in vivo.³

References

1. Yang, Meijia.; et al. "Tandem CAR-T cells targeting CD70 and B7-H3 exhibit potent preclinical activity against multiple solid tumors." Theranostics 10.17 (2020): 7622.
2. Dequeant, Mary Lee.; et al. "Targeting multiple solid tumor types with anti-CD70 allogeneic CAR-T cells." Cancer Research 79.13_Supplement (2019): 3184-3184.
3. Wu, Gongqiang.; et al. "Preclinical evaluation of CD70-specific CAR T cells targeting acute myeloid leukemia." Frontiers in Immunology 14 (2023): 1093750.